Analysts Are Bullish on These Healthcare Stocks: Eli Lilly & Co (LLY), Humana (HUM)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Eli Lilly & Co (LLY – Research Report), Humana (HUM – Research Report) and Quest Diagnostics (DGX – Research Report) with bullish sentiments.

Eli Lilly & Co (LLY)

Bank of America Securities analyst Geoff Meacham maintained a Buy rating on Eli Lilly & Co yesterday and set a price target of $390.00. The company’s shares closed last Thursday at $330.70.

According to TipRanks.com, Meacham is a 4-star analyst with an average return of 5.1% and a 53.9% success rate. Meacham covers the Healthcare sector, focusing on stocks such as Amylyx Pharmaceuticals Inc, BioMarin Pharmaceutical, and Vertex Pharmaceuticals.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Eli Lilly & Co with a $400.20 average price target, implying a 19.8% upside from current levels. In a report issued on January 19, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $432.00 price target.

See today’s best-performing stocks on TipRanks >>

Humana (HUM)

Bank of America Securities analyst Kevin Fischbeck reiterated a Buy rating on Humana yesterday and set a price target of $640.00. The company’s shares closed last Thursday at $489.77.

According to TipRanks.com, Fischbeck is a 4-star analyst with an average return of 4.1% and a 60.9% success rate. Fischbeck covers the Healthcare sector, focusing on stocks such as Alignment Healthcare, Bright Health Group, and Acadia Healthcare.

Currently, the analyst consensus on Humana is a Strong Buy with an average price target of $620.92, representing a 24.4% upside. In a report issued on January 24, Argus Research also maintained a Buy rating on the stock with a $560.00 price target.

Quest Diagnostics (DGX)

In a report released yesterday, Derik De Bruin from Bank of America Securities maintained a Buy rating on Quest Diagnostics, with a price target of $173.00. The company’s shares closed last Thursday at $145.47.

According to TipRanks.com, Bruin is a 4-star analyst with an average return of 5.2% and a 57.3% success rate. Bruin covers the Healthcare sector, focusing on stocks such as Adaptive Biotechnologies, Ginkgo Bioworks Holdings, and Guardant Health.

Currently, the analyst consensus on Quest Diagnostics is a Hold with an average price target of $153.38.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on LLY:

• Pharma Earnings: Q4 Hits and Misses in a Post-COVID-19 World
• Eli Lilly says FDA approves Jaypirca
• Eli Lilly to invest $450M to expand manufacturing at Research Triangle Park
• Eli Lilly, Boehringer: FDA accepts sNDA for Jardiance for adults with CKD
• Donanemab CRL a ‘positive headline’ for Biogen’s Leqembi, says William Blair